Sugi Predict

Sugi Predict / Compounds / SCHEMBL7181647

SCHEMBL7181647

SCHEMBL7181647

COc1cccc(Cl)c1C(=O)[PH](=O)c1c(Cl)ccc(C(=O)c2ccccc2)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ LMNA P02545 6/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ HTT P42858 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ HPGD P15428 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ PGR P06401 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186467 0.95 MAPT (0.44) MAPTKMT2AKDM4EMAPK1HSD17B10
SCHEMBL7180744 0.88 MAPT (0.41) MAPTKMT2AKDM4EMAPK1HSD17B10
SCHEMBL7190116 0.88 RAB9A (0.41) MAPTKMT2AKDM4EMAPK1HSD17B10
SCHEMBL7175461 0.87 MAPT (0.45) MAPTKMT2AKDM4EMAPK1HSD17B10
SCHEMBL7180790 0.86 CA12 (0.41) MAPTKMT2AKDM4EMAPK1HSD17B10
SCHEMBL7179867 0.85 MAPT (0.38) MAPTKMT2ALMNAALDH1A1CYP3A4
SCHEMBL7175667 0.85 MAPT (0.41) MAPTKMT2AKDM4EMAPK1HSD17B10
SCHEMBL7188332 0.84 TUBB4A (0.40) MAPTKMT2AKDM4EMAPK1HSD17B10
SCHEMBL7181182 0.84 TUBB4A (0.39) MAPTKMT2AKDM4EMAPK1HSD17B10
SCHEMBL7182247 0.84 MAPT (0.40) MAPTKMT2AKDM4EMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885KMT2A 1586/4885KDM4E 3226/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885KMT2A 956/4885KDM4E 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.